← All trials
NCT04508205
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2018
- Primary completion
- Apr 18, 2019
- Completion date
- Apr 18, 2019
- First posted
- Aug 11, 2020
- Last posted
- Aug 12, 2020
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CAGE Bio Inc.Lead sponsor
- ethica Clinical Research Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.